BioWorld

April 20, 2006

View Archived Issues

Genzyme's First-Quarter Sales Below Expectations

Genzyme Corp.'s stock dipped on word that first-quarter revenues came in lower than expected, though the $730.8 million number represents a 16 percent rise over the same quarter last year. (BioWorld Today) Read More

CV Therapeutics Gets Line Of Credit For Up To $200M

Read More

Parasite Infections May Provide Dual Anti-Inflammatory Defense

Read More

Canada's Labopharm Files For $76M IPO On Nasdaq

Read More

Clinic Roundup

Read More

Other News To Note

Read More